The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Discovery of an orally active small-molecule irreversible inhibitor of protein disulfide isomerase for ovarian cancer treatment
Open accessAbstract
Protein disulfide isomerase (PDI), an endoplasmic reticulum chaperone protein, catalyzes disulfide bond breakage, formation, and rearrangement. The effect of PDI inhibition on ovarian cancer progression is not yet clear, and there is a need for potent, selective, and safe small-molecule inhibitors of PDI. Here, we report a class of propynoic acid carbamoyl methyl amides (PACMAs) that are active against a panel of human ovarian cancer cell lines. Using fluorescent derivatives, 2D gel electrophoresis, and MS, we established that PACMA 31, one of the most active analogs, acts as an irreversible small-molecule inhibitor of PDI, forming a covalent bond with the active site cysteines of PDI. We also showed that PDI activity is essential for the survival and proliferation of human ovarian cancer cells. In vivo, PACMA 31 showed tumor targeting ability and significantly suppressed ovarian tumor growth without causing toxicity to normal tissues. These irreversible small-molecule PDI inhibitors represent an important approach for the development of targeted anticancer agents for ovarian cancer therapy, and they can also serve as useful probes for investigating the biology of PDI-implicated pathways.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R., Naishadham, D., & Jemal, A. (2012) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20138 · Cited by 10,679
Gene-expression profiles predict survival of patients with lung adenocarcinoma
Beer, D. G., Kardia, S. L. R., Huang, C.-C., Giordano, T. J., Levin, A. M., Misek, D. E., Lin, L., Chen, G., Gharib, T. G., Thomas, D. G., et al. (2002) · Nature Medicine · doi:10.1038/nm733 · Cited by 2,025 · cited 1×
“Increased PDI levels have been documented in a variety of human cancers, including ovarian (8), prostate (9), and lung cancers (10, 11) as well as lymphoma (11), glioma (12, 13), acute myeloid leukemia (7), and melanoma (5, 14).”
BackgroundThe resurgence of covalent drugs
Singh, J., Petter, R. C., Baillie, T. A., & Whitty, A. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3410 · Cited by 1,873
Reverse engineering of regulatory networks in human B cells
Basso, K., Margolin, A. A., Stolovitzky, G., Klein, U., Dalla-Favera, R., & Califano, A. (2005) · Nature Genetics · doi:10.1038/ng1532 · Cited by 1,404
S-Nitrosylated protein-disulphide isomerase links protein misfolding to neurodegeneration
Uehara, T., Nakamura, T., Yao, D., Shi, Z.-Q., Gu, Z., Ma, Y., Masliah, E., Nomura, Y., & Lipton, S. A. (2006) · Nature · doi:10.1038/nature04782 · Cited by 906
Welsh, J. B., Sapinoso, L. M., Su, A. I., Kern, S. G., Wang‐Rodriguez, J., Moskaluk, C. A., Frierson, H. F., & Hampton, G. M. (2001) · PubMed · Cited by 856
Protein Disulfide Isomerase: A Critical Evaluation of Its Function in Disulfide Bond Formation
Hatahet, F., & Ruddock, L. W. (2009) · Antioxidants & Redox Signaling · doi:10.1089/ars.2009.2466 · Cited by 670
Novel Genes Associated with Malignant Melanoma but not Benign Melanocytic Lesions
Talantov, D., Mazumder, A., Yu, J. X., Briggs, T., Jiang, Y., Backus, J., Atkins, D., & Wang, Y. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0683 · Cited by 521
K2D2: Estimation of protein secondary structure from circular dichroism spectra
Perez-Iratxeta, C., & Andrade-Navarro, M. A. (2008) · BMC Structural Biology · doi:10.1186/1472-6807-8-25 · Cited by 470
A Gene Signature Predicting for Survival in Suboptimally Debulked Patients with Ovarian Cancer
Bonome, T., Levine, D. A., Shih, J., Randonovich, M., Pise-Masison, C. A., Bogomolniy, F., Ozbun, L., Brady, J., Barrett, J. C., Boyd, J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6595 · Cited by 439
Rickman, D. S., Bobek, M. P., Misek, D. E., Kuick, R. D., Blaivas, M., Kurnit, D. M., Taylor, J. M. G., & Hanash, S. (2001) · PubMed · Cited by 352
Protein disulfide isomerase: the structure of oxidative folding
Gruber, C. W., Čemažar, M., Heras, B., Martin, J. L., & Craik, D. J. (2006) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2006.06.001 · Cited by 346
Karyotypic complexity of the NCI-60 drug-screening panel.
Roschke, A. V., Tonon, G., Gehlhaus, K., Mctyre, N., Bussey, K. J., Lababidi, S., Scudiero, D. A., Weinstein, J. N., & Kirsch, I. R. (2003) · PubMed · Cited by 316
Inhibitors of protein disulfide isomerase suppress apoptosis induced by misfolded proteins
Hoffstrom, B. G., Kaplan, A., Letso, R., Schmid, R. S., Turmel, G. J., Lo, D. C., & Stockwell, B. R. (2010) · Nature Chemical Biology · doi:10.1038/nchembio.467 · Cited by 310
Protein disulfide isomerase: The multifunctional redox chaperone of the endoplasmic reticulum
Noiva, R. (1999) · Seminars in Cell & Developmental Biology · doi:10.1006/scdb.1999.0319 · Cited by 277
Alvarez, M., Paull, K., Monks, A., Hose, C., Lee, J. S., Weinstein, J., Grever, M., Bates, S., & Fojo, T. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117910 · Cited by 216
LaMantia, M., & Lennarz, W. J. (1993) · Cell · doi:10.1016/0092-8674(93)90469-7 · Cited by 207
Kemmink, J., Darby, N. J., Dijkstra, K., Nilges, M., & Creighton, T. E. (1996) · Biochemistry · doi:10.1021/bi960335m · Cited by 192
Protein Disulfide Isomerase Expression Is Related to the Invasive Properties of Malignant Glioma
Goplen, D., Wang, J., Enger, P. Ø., Tysnes, B. B., Terzis, A. J. A., Laerum, O. D., & Bjerkvig, R. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4589 · Cited by 192
Disulfide bonds in ER protein folding and homeostasis
Feige, M. J., & Hendershot, L. M. (2011) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2010.10.012 · Cited by 183
Jänne, P. A., Boss, D. S., Camidge, D. R., Britten, C. D., Engelman, J. A., Garon, E. B., Guo, F., Wong, S., Liang, J., Letrent, S., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1220 · Cited by 181 · cited 2×
“To date, a large number of irreversible inhibitors have been reported to exhibit anticancer activities, such as α-difluoromethylornithine and covalent EGF receptor inhibitors (HKI-375, HKI-272, EKB569, BIBW2992, and PF299804) (34).”
BackgroundLovat, P. E., Corazzari, M., Armstrong, J. L., Martin, S., Pagliarini, V., Hill, D., Brown, A. M., Piacentini, M., Birch-Machin, M. A., & Redfern, C. P. F. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0035 · Cited by 177
Vuori, K. A. M., Myllylä, R., Pihlajaniemi, T. A., & Kivirikko, K. I. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)42505-7 · Cited by 147
Townsend, D. M., Manevich, Y., He, L., Xiong, Y., Bowers, R. R., Hutchens, S., & Tew, K. D. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0493 · Cited by 139
Validation of putative genomic biomarkers of nephrotoxicity in rats
Wang, E., Snyder, R. D., Fielden, M. R., Smith, R. J., & Gu, Y. (2008) · Toxicology · doi:10.1016/j.tox.2007.12.031 · Cited by 113
Primm, T. P., & Gilbert, H. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m007670200 · Cited by 104
Maola, K. M. G., Simizu, S., Lai, N. S., Kawatani, M., Shimizu, T., & Osada, H. (2010) · ACS Chemical Biology · doi:10.1021/cb100387r · Cited by 83
江島, 邦., Nanri, H., Araki, M., Uchida, K., Kashimura, M., & Ikeda, M. (1999) · European Journal of Endocrinology · doi:10.1530/eje.0.1400608 · Cited by 69
Tissue-Specific Pathways for Estrogen Regulation of Ovarian Cancer Growth and Metastasis
Spillman, M. A., Manning, N. G., Dye, W. W., Sartorius, C. A., Post, M. D., Harrell, J. C., Jacobsen, B. M., & Horwitz, K. B. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1238 · Cited by 67
Platelet cell-surface protein disulphide-isomerase mediated S-nitrosoglutathione consumption
Root, P. D., Sliskovic, I., & Mutus, B. (2004) · Biochemical Journal · doi:10.1042/bj20040759 · Cited by 63
Haefliger, S., Klebig, C., Schaubitzer, K., Schardt, J., Timchenko, N. A., Mueller, B. U., & Pabst, T. (2011) · Blood · doi:10.1182/blood-2010-08-304485 · Cited by 60
Protein disulfide isomerases are antibody targets during immune-mediated tumor destruction
Fonseca, C., Soiffer, R. J., Ho, V. T., Vanneman, M. W., Jinushi, M., Ritz, J., Neuberg, D. S., Stone, R. M., DeAngelo, D. J., & Dranoff, G. (2008) · Blood · doi:10.1182/blood-2007-09-114157 · Cited by 39
Yamada, R., Cao, X., Butkevich, A. N., Millard, M., Odde, S., Mordwinkin, N., Gundla, R., Zandi, E., Louie, S. G., Petasis, N. A., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm101655d · Cited by 36
Self-citation
Cited by
Endoplasmic reticulum stress signalling-from basic mechanisms to clinical applications
Almanza, A., Carlesso, A., Chintha, C., Creedican, S., Doultsinos, D., Leuzzi, B., Luís, A., McCarthy, N., Montibeller, L., More, S., et al. (2019) · The FEBS Journal · doi:10.1111/febs.14608 · Cited by 1,034
Protein disulfide isomerase: a promising target for cancer therapy
Xu, S., Sankar, S., & Neamati, N. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2013.10.017 · Cited by 278
Self-citationBroad-spectrum antivirals against viral fusion
Vigant, F., Santos, N. C., & Lee, B. (2015) · Nature Reviews Microbiology · doi:10.1038/nrmicro3475 · Cited by 266
Protein disulfide isomerases: Redox connections in and out of the endoplasmic reticulum
Soares Moretti, A. I., & Martins Laurindo, F. R. (2017) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2016.11.007 · Cited by 140
Targeting the unfolded protein response for disease intervention.
Rivas, A., Vidal, R. L., & Hetz, C. (2015) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2015.1053869 · Cited by 62
“In addition, PDI inhibitors have potent anticancer effects in preclinical models of the disease [80].”
Background
Metadata
- Authors
- Xu, S., Butkevich, A. N., Yamada, R., Zhou, Y., Debnath, B., Duncan, R., Zandi, E., Petasis, N. A., & Neamati, N.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2012-09-17
- Volume
- 109
- Issue
- 40
- Pages
- 16348-16353
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2033199474
- Cited by
- 253
- References
- 33
- FWCI
- 7.52
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.